Clinical trials: Calcific Uremic Arteriolopathy (CUA)
Rheopheresis, Calcifying Uremic Arteriolopathy
Retrospective Study Evaluating the Contribution of Rheopheresis in the Treatment of Uremic Calciphylaxis (RHEO-CUA)
Calcifying uremic arteriolopathy (or uremic calciphylaxis) is a rare disease (prevalence <1% of dialysis patients), but the prognosis is often catastrophic.
- Conditions
- Rheopheresis, Calcifying Uremic Arteriolopathy, Uremic Calciphylaxis
- Trial name
- RHEO-CUA (NCT05633121)
- Testing
- Rheopheresis
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Association ECHO
Calcific Uremic Arteriolopathy (CUA), Calciphylaxis
European Calciphylaxis Registry Network
Observational, registry, prospective, non-interventional collection of CUA patient data. Patient treatment is carried out within clinical routine, at the discretion of the physicians and according to existing treatment…
- Trial name
- EuCalNet (NCT02635373)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- RWTH Aachen University